Postmenopausal osteoporosis is a condition that weakens bones, making them brittle and prone to fracture. Taking the hormone estradiol can reverse these effects, but it may also increase endometrial and uterine cancer risks. Researchers publishing in Nano Letters developed a two-layer shell to encapsulate the hormone so it bypasses the uterus and releases only within an osteoporotic bone. Tests of the drug-delivery system showed improved bone density in treated mice without uterine side effects.
This article was originally published on MedicalXpress.com
